Reimagining Medicine

Company overview Innovation: Pipeline overview Financial review Novartis pipeline in Phase 1 Solid tumors Code Name 177Lu-NeoB 225AC-PSMA-617 Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA 2023 priorities Appendix Innovation: Clinical trials Abbreviations Hematology Indication(s) Code Multiple solid tumors ADPT03 Metastatic castration-resistant prostate cancer Colorectal cancer (combos) HDM201 Name ADPT03 HDM201 (combos) JBH492 JBH492 Renal cell carcinoma Cancers JEZ567 JEZ567 MAK683 Unveal melanoma MBG453 MAK683 sabatolimab Mesothelioma MIK665 MIK665 KRAS G12C mutated solid tumors PIT565 PIT565 Solid tumors VAY736 ianalumab + ibrutinib BAFF-R inhibitor Solid tumors VOB560 VOB560 NSCLC Solid tumors WVT078 YTB323 WVT078 rapcabtagene autoleucel CD19 CAR-T Solid tumors AAA603 AAA817 ADPT01 ADPT01 DFF332 DFF332 HIF2A inhibitor DKY709 DKY709 + spartalizumab DYP688 DYP688 IAG933 IAG933 JDQ443 JDQ443 Novel immunomodulatory agent GNAQ,GNA11 antagonist. KRAS inhibitor KAZ954 KAZ954 KFA115 KFA115 MGY825 MGY825 NIS793 NIS793, spartalizumab Novel immunomodulatory Agent TGFB inhibitor NIZ985 NIZ985, spartalizumab IL-15 agonist NZV930 NZV930, spartalizumab, NIR178 TNO155 TNO155 VPM087 WNT974 gevokizumab WNT974+ spartalizumab CD73 antagonist SHP2 inhibitor IL-1 beta antagonist Porcupine inhibitor Solid tumors Solid tumors (combo) Cardiovascular Colorectal cancer, 1st line Solid tumors Code XXB750 Name XXB750 Immunology Others Code Name FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 NG1226 NGI226 Mechanism Indication(s) Non-alcoholic steatohepatitis (NASH) Autoimmune indications Systemic lupus erythematosus Tendinopathy Code Name Global Health EDI048 EYU688 EDI048 EYU688 KAF156 INE963 ganaplacide INE963 Neuroscience Code NIO752 Ophthalmology Name NIO752 Mechanism Indication(s) MHU650 MHU650 Tau antagonist Progressive supranuclear palsy 53 Investor Relations | Q4 2022 Results 30 lead indications Lead indication Mechanism BCL11A MDM2 inhibitor CD123 CAR-T EED inhibitor TIM3 antagonist MCL1 inhibitor Indication(s) Sickle cell anemia Hematological malignancy Hematological malignancy Acute myeloid leukemia Cancers Low risk myelodysplastic syndrome Hematological malignancies B-cell malignancies Hematological malignancy (combo) Cancers Multiple myeloma Adult ALL Mechanism NPR1 agonist Indication(s) Cardiovascular diseases Mechanism CpPI(4)K inhibitor NS4B inhibitor Non-artemisinin plasmodium falciparum inhibitor Indication(s) Cryptosporidiosis Dengue Malaria prophylaxis Malaria, uncomplicated Diabetic eye diseases NOVARTIS | Reimagining Medicine

View entire presentation